Developing novel medicines for serious immune system disorders
Recent News
At Zura Bio, our mission is centered on enhancing the well-being of patients living with severe autoimmune and inflammatory conditions by developing novel medicines to dramatically improve their lives.
Our approach focuses on dual-pathway biology, signifying a potential paradigm shift for patients who currently find their needs underserved by single-pathway medicines. We aim to showcase the unique benefits of our portfolio, striving to meet the distinct needs of our therapeutic areas and make a tangible difference in patients’ well-being.
About Zura Bio
Zura Bio is led by a team of biotechnology entrepreneurs and pharmaceutical industry professionals with a proven track record of successfully identifying and developing innovative medicines that advance patient care and improve their well-being.
Pipeline
We are currently developing a portfolio of therapeutic indications for tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience.
Investors
Find our latest news, events, presentations, and financial updates.
Nasdaq Ticker: ZURA